March 20 - Corporate Dealmaker (The Deal) - The creative use of bio-bucks, trends in due diligence and the latest on the balance of power in the industry were the key takeaways Wednesday when dealmakers from four prominent companies shared their thoughts in a couple of sessions at The Deal's Healthcare Dealmaking Symposium in New York.
It's no secret that the medicine business has long been characterized by an elaborate pas de trois performed by Big Pharma, biotech and the financial markets. What attendees saw were some of the very latest moves in this long-running dance.
Representing big pharmas that are working to restructure, divest and replenish their pipelines were Robert Knowles, who works in biz dev for Pfizer Inc., and Charles Simmons, who does the same for Bristol-Myers Squibb Co. Also on hand was June Nguyen of Eisai Inc., who has played a big role as the Japanese pharma has built its U.S. presence and used biotech acquisitions to build an oncology business. On the biotech side was Annarie Lyles, head of biz dev for Genmab Inc. Read more and view video clips.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment